September 23, 2021

Credence Turbine

Pin to Mountain

herceptin biosimilar market

Herceptin biosimilar market predicted to hit US$ 6.5 billion by 2028

The herceptin biosimilar market size is expected to reach over US$ 6.5 billion by 2028. The increasing prevalence of cancer worldwide along with rising product launches by key players are the key factors for herceptin biosimilar market growth. The herceptin biosimilar market report further mentioned that the market size raised at US$ 1.1 billion in 2019, and it is likely to exhibit a Compound annual growth rate (CAGR) of 25.1% during the forecast period 2020 to 2028.

The increasing prevalence of cancer

The increasing prevalence of numerous cancer such as breast cancer, gastric cancer, and others across the globe is one of the key drivers for market growth. According to a recent report published in 2019, by the International Agency for Research on Cancer (IARC) and GLOBOCAN, the global cancer burden has risen to 18.1 million cases and 9.6 million cancer deaths. Moreover, the rising pollution and changing consumer lifestyle coupled with the adoption of smoking are some other key factors anticipated to enhance the global herceptin biosimilar market over the upcoming years.

Get Sample Copy Here: https://www.alchemymarketresearch.com/healthcare/herceptin-biosimilar-market

Rising demand from developing countries

The increasing demand for herceptin biosimilar in emerging economies such as India, China, Brazil, and others along with rising spending on research & development are some other key factors for the growth of the global herceptin biosimilar market during the forecast period. The rising product launches by key players is another major reason for global market growth. For instance, in March 2020, Celltrion Healthcare and Teva Pharmaceutical Industries Ltd. introduced trastuzumab biosimilar Herzuma (trastuzumab-pkrb) in the US. Herzuma can be used to treat breast and gastric cancer and has recently been approved in Canada. However, the presence of alternatives along with the side effects of herceptin biosimilar are estimated to hinder the market growth over the forecast period.

Alchemy Research and Analytics LLP, has observed the impact of the ongoing COVID‑19 pandemic on the herceptin biosimilar market for the years 2020 and 2021. As per our extensive secondary and primary research, the demand for herceptin biosimilar has decreased. For instance, in July 2020, a leading manufacturer of oncology medicines Roche Holding AG stated that its top three selling biosimilar products, Rituxan, Herceptin, and Avastin experienced a reduction in sales of around 33%, 46%, and 29% respectively during the COVID- 19 period.

Key Manufacturers Aim to Enhance Their Portfolios by Partnerships

According to Alchemy Research and Analytics major market players in the herceptin biosimilar market are focusing on strategies such as partnerships, collaboration, acquisitions, and mergers to enhance their geographic presence as well as product portfolio. The herceptin biosimilar market is highly fragmented.

Alchemy Market Research lists out the names of key market players in the herceptin biosimilar market. They are as follows:

  • Amgen Inc.
  • Aryogen Biopharma
  • Biocon Limited
  • Celltrion Inc.
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Accord Healthcare Ltd.
  • Gedeon Richter PLC
  • Genor Biopharma Company Ltd.
  • Mabion S.A.
  • Mylan N.V.
  • Roche Holding AG

A Significant Industry Development-

June 2019: Allergan PLC and Amgen Inc. announced that the United Stated Food & Drug Administration (FDA) approved  KANJINTI (trastuzumab-anns) for all approved indications of the reference product, Herceptin (trastuzumab):  for the treatment of HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. KANJINTI was proven to be highly similar to, and to have no clinically meaningful differences from, Herceptin based on a comprehensive totality of evidence which included extensive comparative analytical, pharmacokinetic, and clinical data. At the time of approval, KANJINTI is the only trastuzumab biosimilar to incorporate the evaluation of a single transition in the clinical study, demonstrating similar safety and immunogenicity in patients who were previously on Herceptin.

Further Report Findings-

  • The Asia Pacific is presumed to witness the fastest growth in the years to come due to rising cases of breast and gastric cancer in the region. The rising product launches by key players in the region along with rising consumer focus towards a healthy lifestyle are other key factors for market growth.
  • North America accounted for the largest share in the global herceptin biosimilar market owing to the rising cases of breast cancer along with the presence of key players in the region. The U.S. accounted for the largest share in the North America herceptin biosimilar market in 2019.
  • Based on end user, the herceptin biosimilar market is bifurcated into hospitals, oncology centers, and others. The hospital category accounted for the largest share in 2019 and accounted for over 50% of the market revenue share in the same year. This is mainly due to the rising number of specialist cancer hospitals across the globe.

Get Sample Copy Here: https://www.alchemymarketresearch.com/healthcare/herceptin-biosimilar-market